Opzelura (ruxolitinib 1.5%) cream - Brand New & Sealed

FAQ - Opzelura (Ruxolitinib) Cream Brand New, Sealed, In Box, What is Opzelura? Opzelura (ruxolitinib 1.5%) cream is a topical selective Janus kinase (JAK) inhibitor approved by the FDA for the short-term and non-continuous treatment of mild to moderate atopic dermatitis in non-immunocompromised (patients without weakened immune systems) adult and pediatric patients 12 years of age and older who disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Mild to moderate atopic dermatitis is generally determined by skin involvement (how much of your body surface is affected) and severity of symptoms such as itch and rash. It’s important to talk to your doctor about how atopic dermatitis affects not just your skin but also other aspects of your life. Together, you and your healthcare provider can determine if Opzelura is an appropriate treatment option. How does Opzelura work? Opzelura is not a topical steroid. It works by specifically blocking JAK1 and JAK2, two enzymes that are involved in several cytokine pathways that contribute to inflammation in the skin, itch, and skin barrier function. Reducing the activity of JAK1 and JAK2 in atopic dermatitis can lead to fewer and/or less severe signs and symptoms by reducing itch, rash, and skin redness. How do you use Opzelura? Opzelura (ruxolitinib 1.5%) is applied as a thin film directly to the affected areas of skin twice daily (up to 20% of the body surface area for up to 8 weeks). Additional usage should be discussed with your healthcare provider. How effective is Opzelura for atopic dermatitis? In two Phase 3 clinical trials for Opzelura1, after 8 weeks of continuous use: 53.8% and 51.3% of patients achieved the primary endpoint Investigator Global Assessment-Treatment Success (IGA-TS) of 0-1 (clear or almost clear) with at least a 2-grade improvement from the start of the trial. This improvement compared with 7.6% of those using a vehicle only. Investigator Global Assessment (IGA) is a 5-point scale that provides a global clinical assessment of atopic dermatitis by the investigator, based on signs and symptoms. Secondary endpoints in these trials after 8 weeks of continuous use included: Proportion of patients achieving a 75% improvement in the Eczema Area and Severity Index (EASI-75; an investigator tool used to measure the extent (area) and severity of atopic dermatitis): 62.1% and 61.8% of patients using Opzelura achieved EASI-75 Proportion of patients with a reduction in itch severity (NRS4; at least a 4-point decrease on an 11-point (0-10) numeric rating scale) 52.2% and 50.7% of patients using Opzelura achieved NRS4 Reductions in itch began as early as 12 hours after first application. Proportion of patients with improved sleep quality (at least a 6-point improvement (out of 40 maximum) rated using an 8-question form) 22.3% and 25.6% of patients using Opzelura improved sleep quality

Condition

New